Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mastectomy, Segmental | 38 | 2017 | 974 | 3.370 |
Why?
|
| Breast Neoplasms | 69 | 2017 | 21162 | 2.330 |
Why?
|
| Radiotherapy, Adjuvant | 23 | 2016 | 1787 | 1.440 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 13 | 2016 | 934 | 1.420 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2017 | 9404 | 1.220 |
Why?
|
| Radiation Oncology | 10 | 2016 | 571 | 1.160 |
Why?
|
| Mastectomy | 9 | 2017 | 1861 | 0.990 |
Why?
|
| Lymphatic Metastasis | 10 | 2016 | 2901 | 0.690 |
Why?
|
| Patient Selection | 5 | 2016 | 4252 | 0.680 |
Why?
|
| Brachytherapy | 4 | 2016 | 1220 | 0.660 |
Why?
|
| Neoplasm, Residual | 4 | 2017 | 1012 | 0.530 |
Why?
|
| Lymph Nodes | 6 | 2016 | 3468 | 0.490 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2014 | 90 | 0.430 |
Why?
|
| Neoplasm Staging | 18 | 2016 | 11218 | 0.420 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2016 | 1097 | 0.410 |
Why?
|
| Receptors, Progesterone | 6 | 2012 | 1159 | 0.390 |
Why?
|
| Consensus | 4 | 2016 | 3208 | 0.390 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2013 | 794 | 0.380 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 480 | 0.370 |
Why?
|
| Receptors, Estrogen | 8 | 2012 | 2251 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2015 | 3552 | 0.360 |
Why?
|
| Disease-Free Survival | 9 | 2016 | 6850 | 0.350 |
Why?
|
| Combined Modality Therapy | 14 | 2016 | 8540 | 0.350 |
Why?
|
| Patient Preference | 2 | 2013 | 946 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 4 | 2015 | 2902 | 0.300 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 442 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 8 | 2015 | 3609 | 0.280 |
Why?
|
| Societies, Medical | 6 | 2016 | 3957 | 0.270 |
Why?
|
| Receptor, erbB-2 | 7 | 2012 | 2597 | 0.270 |
Why?
|
| Lymph Node Excision | 7 | 2012 | 1267 | 0.270 |
Why?
|
| Follow-Up Studies | 18 | 2017 | 39309 | 0.260 |
Why?
|
| Female | 71 | 2017 | 396520 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2014 | 2340 | 0.240 |
Why?
|
| Radiotherapy Dosage | 9 | 2011 | 2911 | 0.240 |
Why?
|
| Genetic Markers | 1 | 2011 | 2603 | 0.230 |
Why?
|
| Age Factors | 10 | 2016 | 18397 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2016 | 10384 | 0.210 |
Why?
|
| Lymphedema | 2 | 2016 | 526 | 0.210 |
Why?
|
| Humans | 75 | 2017 | 766766 | 0.190 |
Why?
|
| Prognosis | 12 | 2017 | 29948 | 0.190 |
Why?
|
| Postoperative Period | 2 | 2016 | 1824 | 0.180 |
Why?
|
| Mammography | 4 | 2008 | 2429 | 0.180 |
Why?
|
| Sentinel Lymph Node Biopsy | 5 | 2011 | 734 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 3 | 2014 | 1061 | 0.170 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2013 | 877 | 0.170 |
Why?
|
| Middle Aged | 34 | 2017 | 223257 | 0.170 |
Why?
|
| Axilla | 4 | 2012 | 622 | 0.160 |
Why?
|
| Lymphatic Irradiation | 2 | 2010 | 115 | 0.160 |
Why?
|
| Aged, 80 and over | 13 | 2016 | 59550 | 0.150 |
Why?
|
| Research | 2 | 2012 | 1977 | 0.150 |
Why?
|
| Radiation Dosage | 5 | 2014 | 1957 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2016 | 7431 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2011 | 3591 | 0.140 |
Why?
|
| Time Factors | 8 | 2016 | 40149 | 0.140 |
Why?
|
| Radiotherapy | 3 | 2014 | 1497 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 3485 | 0.140 |
Why?
|
| Survival Rate | 7 | 2012 | 12825 | 0.130 |
Why?
|
| Treatment Outcome | 15 | 2014 | 65273 | 0.130 |
Why?
|
| Aged | 24 | 2016 | 171343 | 0.130 |
Why?
|
| Adult | 27 | 2016 | 223307 | 0.130 |
Why?
|
| Reoperation | 4 | 2017 | 4325 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6512 | 0.120 |
Why?
|
| Advisory Committees | 2 | 2009 | 797 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2011 | 6214 | 0.110 |
Why?
|
| Risk Factors | 9 | 2017 | 74881 | 0.110 |
Why?
|
| Career Choice | 2 | 2012 | 768 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 598 | 0.110 |
Why?
|
| United States | 17 | 2016 | 72951 | 0.100 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 213 | 0.100 |
Why?
|
| Informed Consent | 2 | 2009 | 1010 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2016 | 54871 | 0.100 |
Why?
|
| Retrospective Studies | 14 | 2016 | 81635 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2015 | 1900 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 1 | 2013 | 1622 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 3692 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2005 | 2234 | 0.090 |
Why?
|
| Specialty Boards | 1 | 2012 | 235 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2013 | 10100 | 0.080 |
Why?
|
| Fluorouracil | 2 | 2005 | 1651 | 0.080 |
Why?
|
| Radiation Pneumonitis | 2 | 2006 | 99 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2007 | 5943 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2017 | 41710 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2009 | 967 | 0.070 |
Why?
|
| Methotrexate | 2 | 2005 | 1719 | 0.070 |
Why?
|
| Estrogen Antagonists | 1 | 2008 | 151 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2014 | 1574 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2011 | 11872 | 0.070 |
Why?
|
| Breast | 1 | 2016 | 1971 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2008 | 4891 | 0.070 |
Why?
|
| Heart Diseases | 2 | 2014 | 2817 | 0.070 |
Why?
|
| Career Mobility | 2 | 2007 | 262 | 0.070 |
Why?
|
| SEER Program | 3 | 2011 | 1443 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2014 | 2764 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 12534 | 0.060 |
Why?
|
| Neoplasms | 1 | 2014 | 22350 | 0.060 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2006 | 523 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2006 | 507 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 1667 | 0.060 |
Why?
|
| Mammaplasty | 3 | 2010 | 1268 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2011 | 8045 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2005 | 348 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 15416 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2009 | 36567 | 0.050 |
Why?
|
| Research Subjects | 1 | 2005 | 248 | 0.050 |
Why?
|
| Antineoplastic Protocols | 1 | 2002 | 48 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2005 | 2229 | 0.050 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 13643 | 0.050 |
Why?
|
| Inhalation | 1 | 2002 | 142 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2234 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2006 | 802 | 0.050 |
Why?
|
| Risk | 2 | 2011 | 9602 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 1536 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 1741 | 0.050 |
Why?
|
| Observer Variation | 1 | 2007 | 2614 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2009 | 2253 | 0.040 |
Why?
|
| Young Adult | 3 | 2016 | 59939 | 0.040 |
Why?
|
| Mesothelioma | 1 | 2006 | 774 | 0.040 |
Why?
|
| Italy | 1 | 2002 | 856 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2002 | 15831 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2006 | 1155 | 0.040 |
Why?
|
| Teaching | 1 | 2007 | 1171 | 0.040 |
Why?
|
| Disclosure | 1 | 2005 | 755 | 0.040 |
Why?
|
| Incidence | 5 | 2014 | 21525 | 0.040 |
Why?
|
| Radiology | 1 | 2012 | 2105 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2007 | 1226 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2005 | 1274 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2005 | 1259 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2005 | 1727 | 0.040 |
Why?
|
| Survivors | 2 | 2014 | 2379 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2011 | 3242 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2006 | 1885 | 0.040 |
Why?
|
| Disease Progression | 1 | 2014 | 13640 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 168 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 8621 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1194 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2005 | 2418 | 0.030 |
Why?
|
| Research Design | 1 | 2008 | 6207 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 24295 | 0.020 |
Why?
|
| Curriculum | 1 | 2005 | 3783 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 9101 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4853 | 0.020 |
Why?
|
| Radiography | 1 | 2002 | 6968 | 0.020 |
Why?
|
| Sarcoma | 1 | 2002 | 1802 | 0.020 |
Why?
|
| Logistic Models | 3 | 2011 | 13278 | 0.020 |
Why?
|
| Utilization Review | 1 | 2011 | 381 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 1697 | 0.020 |
Why?
|
| Mastectomy, Extended Radical | 1 | 2008 | 3 | 0.020 |
Why?
|
| Authorship | 1 | 2012 | 289 | 0.020 |
Why?
|
| Faculty | 1 | 2012 | 383 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 784 | 0.020 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2008 | 62 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2012 | 697 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 12064 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2010 | 564 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 6359 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 300 | 0.020 |
Why?
|
| Employment | 1 | 2012 | 1110 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2011 | 670 | 0.020 |
Why?
|
| Guanine | 1 | 2006 | 280 | 0.020 |
Why?
|
| Glutamates | 1 | 2006 | 384 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2002 | 4904 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2010 | 904 | 0.010 |
Why?
|
| Breast Diseases | 1 | 2007 | 441 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 1986 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2012 | 2504 | 0.010 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 115 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 20708 | 0.010 |
Why?
|
| Melanoma | 1 | 2002 | 5700 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2008 | 811 | 0.010 |
Why?
|
| Medicare | 2 | 2011 | 6820 | 0.010 |
Why?
|
| Forecasting | 1 | 2011 | 2936 | 0.010 |
Why?
|
| Genes, BRCA1 | 1 | 2006 | 753 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2002 | 6962 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 168930 | 0.010 |
Why?
|
| Mentors | 1 | 2007 | 671 | 0.010 |
Why?
|
| Cardiac Volume | 1 | 2002 | 196 | 0.010 |
Why?
|
| Cisplatin | 1 | 2006 | 1655 | 0.010 |
Why?
|
| Diaphragm | 1 | 2002 | 357 | 0.010 |
Why?
|
| Biopsy | 1 | 2011 | 6779 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3601 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 2659 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2011 | 9661 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2006 | 1147 | 0.010 |
Why?
|
| Calcinosis | 1 | 2007 | 1480 | 0.010 |
Why?
|
| Smoking | 1 | 2014 | 9077 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 1241 | 0.010 |
Why?
|
| Educational Status | 1 | 2005 | 2510 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 13485 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2005 | 2021 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 8066 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2010 | 4306 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 5306 | 0.010 |
Why?
|
| Women's Health | 1 | 2002 | 2081 | 0.010 |
Why?
|
| Male | 4 | 2014 | 364142 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 9244 | 0.010 |
Why?
|
| Prevalence | 1 | 2006 | 15835 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 7841 | 0.000 |
Why?
|
| Heart | 1 | 2002 | 4425 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15657 | 0.000 |
Why?
|
Concepts
(199)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(45)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_